US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

27.37

+0.01270.05%

Post-market: 27.500.1304+0.48%16:10 EDT

Volume:1K

Turnover:32.81K

Market Cap:2.46M

PE:- -

High:27.50

Open:27.40

Low:27.37

Close:27.36

52wk High:28.89

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:3.97

T/O Rate:1.33%

Dividend:0.45

Dividend Rate:1.65%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

Upstream Bio presents results from VALIANT trial at ERS Congress

Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement

VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

Inventiva announces last patient visit in NATiV3 trial

PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates

BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics

Celcuity To Participate in Upcoming Investor Conferences

Satellos to Participate in Upcoming Investor Conferences

Novartis halts autoimmune CAR-T trials following three deaths, Reuters says

FutureChem sets final issue price for paid-in capital increase

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease

NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210

Vogenx initiated with a Buy at Jones

SciSparc subsidiary provides update on SCI-210 trial enrollment

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/NVIB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":27.3696,"timestamp":1789156800000,"preClose":27.3569,"halted":0,"volume":1193,"hourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"delay":0,"changeRate":0.000464233886149338,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.0127,"latestTime":"09-11 16:00:00 EDT","open":27.401,"high":27.5,"low":27.3696,"amount":32812,"amplitude":0.004767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":27.3569,"nav":27.337,"aum":2460334.39,"dividendRate":0.016467,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":27.5,"preClose":27.3696,"latestTime":"16:10 EDT","volume":6,"amount":164.2176,"timestamp":1789157404751,"change":0.1304,"changeRate":0.004764,"amplitude":0},"volumeRatio":3.974015203722743},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.974015203722743,"shares":90001,"dividePrice":0.4507,"high":27.5,"amplitude":0.004767,"preClose":27.3569,"low":27.3696,"week52Low":24.54,"pbRate":"--","week52High":28.8896,"institutionHeld":0,"latestPrice":27.3696,"eps":0,"divideRate":0.016467,"volume":1193,"delay":0,"ttmEps":0,"open":27.401,"prevYearClose":25,"prevWeekClose":28.8896,"prevMonthClose":27.4504,"prevQuarterClose":25,"fiveDayClose":28.4889,"twentyDayClose":28.3265},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665321351","title":"Press Release: Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2665321351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665321351?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:00","pubTimestamp":1788861600,"startTime":"0","endTime":"0","summary":"BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc.  , a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended June 30, 2026 and a cash dividend.Financial and Operational Highlights for the Second Quarter of 2026-- Strong Core Business Growth: Net operating revenue for the second quarter. rose to RMB1,448.2 million , representing a robust. year-over-year increase of 72.8%. Insurance-related income for the. quarter reached RMB1,333.2 million , up 80.5% from the. -- Improved Operating Performance: In the second quarter of 2026, operating","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4539","WDH","MEDX","IDNA","QTOC","HYLG","BK4173","AIPO","BK4509","ARTY","CHAT","NVIB","AGIX","VTHR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665326159","title":"Upstream Bio presents results from VALIANT trial at ERS Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2665326159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665326159?lang=en_us&edition=fundamental","pubTime":"2026-09-08 17:10","pubTimestamp":1788858619,"startTime":"0","endTime":"0","summary":"Upstream Bio (UPB) presented results from the Phase 2 VALIANT clinical trial evaluating the safety and efficacy of verekitug in adults with severe ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/upstream-bio-presents-results-from-valiant-trial-at-ers-congress-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","IDNA","BK4139","UPB","MEDX","NVIB","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665157325","title":"Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2665157325","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665157325?lang=en_us&edition=fundamental","pubTime":"2026-09-08 15:30","pubTimestamp":1788852600,"startTime":"0","endTime":"0","summary":"– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","TSLI","TSLL","TSLT","TSLS","TSLO","MEDX","TESL","07366","07766","TSL","TSII","TSLW","IDNA","NVIB","TSYY","CRSH","TSLQ","TESC","TSLR","TSLG","TEST","09366","09766","TSLP","ELOL","TLA","TSLZ","HYLG","TSDD","TSLY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665354019","title":"Guardant announces FDA approval of Guardant360 CDx as companion diagnostic","url":"https://stock-news.laohu8.com/highlight/detail?id=2665354019","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665354019?lang=en_us&edition=fundamental","pubTime":"2026-09-05 06:15","pubTimestamp":1788560112,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that the U.S. Food and Drug Administration has approved Guardant360 CDx as a companion diagnostic to identify patien...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-fda-approval-of-guardant360-cdx-as-companion-diagnostic-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","HELX","BBP","EKG","GNOM","IYH","LU0889565916.HKD","NVIB","IDNA","PTH","IEIH","GNMX","TECB","FFOX","BK4196","BK4588","MRNY","GH","PSCH","SYNB","LU0320765992.SGD","PINK","IBB","LFSC","MRNX","TBXU","BK4551","GDOC","BMED","XLVX","LU0109394709.USD","BK4535","BK4585","LABU","MEDI","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665325354","title":"Polyrizon Raises $4 Million in Registered Direct Offering and Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2665325354","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665325354?lang=en_us&edition=fundamental","pubTime":"2026-09-05 05:18","pubTimestamp":1788556694,"startTime":"0","endTime":"0","summary":"Polyrizon Ltd. ( ($PLRZ) ) has provided an update. Polyrizon Ltd., a NASDAQ-listed development-stage biotech based in Raanana, Israel, is building ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polyrizon-raises-4-million-in-registered-direct-offering-and-private-placement-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","QQQJ","03086","JEPQ",".IXIC","MNQmain","QQQY","SQQQ","ONEQ","NVIW.SI","TECS","GPIQ","QLD","TQQY","QQQE","QID","PSQ","XBIX","NVIB","FTEC","QDTE","TQQQ","NDX","IYW","QYLG","QQQM","QQQ","QQQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808804","title":"VOOLT launches deeptech strategy with co‑investment in biotech firm Pikralida","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808804","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808804?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:21","pubTimestamp":1788445268,"startTime":"0","endTime":"0","summary":"VOOLT Spolka Akcyjna ( ($PL:VLT) ) just unveiled an update. VOOLT S.A. has made its first investment under a new deeptech‑focused strategy, committ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/voolt-launches-deeptech-strategy-with-coinvestment-in-biotech-firm-pikralida?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VLT","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664844613","title":"New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2664844613","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664844613?lang=en_us&edition=fundamental","pubTime":"2026-09-03 05:50","pubTimestamp":1788385800,"startTime":"0","endTime":"0","summary":"Results support the clinical rationale for RASolve 301, an ongoing Phase 3 trial in RAS mutant metastatic non-small cell lung cancer REDWOOD CITY, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) --  Revoluti","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355564/0/en/new-england-journal-of-medicine-publishes-phase-1-2-clinical-data-on-revolution-medicines-rasonque-daraxonrasib-in-metastatic-non-small-cell-lung-cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","IE0009354923.USD","LU2357305700.SGD","IE00BJJMRZ35.SGD","BK4605","BBH","NVIB","BMED","BK4588","CANC","LU0724618433.USD","RVMD","L","IE00BD6J9T35.USD","LU0320765992.SGD","LU1854103824.USD","IE00B2B36J28.USD","BK4139","LU0109394709.USD","IE0002141913.USD","IDNA","LU2298322129.HKD","LU0053666078.USD","LU1983260115.SGD","LU0889565916.HKD","LU1861219969.SGD","LU1978683503.SGD","LU2360107325.USD","ONX","IE00BFMHRM44.USD","LU0124384867.USD","BK4585","BK4512","IE00BZ199S13.USD","LU1548497426.USD","BK4141","BK4107","ONG","ON","LU1854104046.USD","LU1861215975.USD","LU2487616109.SGD","LU1861220033.SGD","LU0348723411.USD","GDOC","IE00B4R5TH58.HKD","IE0009355771.USD","PTH","LU1720051017.SGD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664841533","title":"Inventiva announces last patient visit in NATiV3 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664841533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664841533?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:35","pubTimestamp":1788381316,"startTime":"0","endTime":"0","summary":"Inventiva (IVA) announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial evaluating lanifibranor for...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inventiva-announces-last-patient-visit-in-nativ3-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","BK4139","IDNA","NVIB","MEDX","HYLG","IVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890506","title":"PegBio Partners SN BioScience to Advance Long-Acting Metabolic Peptide Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890506","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664890506?lang=en_us&edition=fundamental","pubTime":"2026-09-02 17:08","pubTimestamp":1788340086,"startTime":"0","endTime":"0","summary":"PegBio Co., Ltd. Class H ( ($HK:2565) ) has shared an update. PegBio has entered a material transfer agreement with Korean biotech SN BioScience to...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pegbio-partners-sn-bioscience-to-advance-long-acting-metabolic-peptide-candidates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2242644610.SGD","XBIX","LU0128526141.USD","LU0029874061.USD","NVIB","SN","BK4191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LENZ","BK4581","XBI","BK4539","XBIX","BK4139","NVIB","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664851222","title":"Celcuity To Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664851222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664851222?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265800,"startTime":"0","endTime":"0","summary":"MINNEAPOLIS, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354143/0/en/celcuity-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664085583","title":"Satellos to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664085583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664085583?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:00","pubTimestamp":1788260400,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative mus","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3353948/0/en/satellos-to-participate-in-upcoming-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","NVIB","GDOC","MSLE","BK4139","MEDX","BMED","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664985383","title":"Novartis halts autoimmune CAR-T trials following three deaths, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664985383","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664985383?lang=en_us&edition=fundamental","pubTime":"2026-09-01 18:30","pubTimestamp":1788258648,"startTime":"0","endTime":"0","summary":"Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after thr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-halts-autoimmune-car-t-trials-following-three-deaths-reuters-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","IE0009355771.USD","NVIB","LU0211331839.USD","BK4532","BK4578","IE00B2B36J28.USD","SYNB","IE00B4R5TH58.HKD","CNCR","BMED","GDOC","LFSC","FBT","LU0070302665.USD","NVS","GNOM","HYLG","LU0320765489.SGD","IBB","PPH","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","MEDX","TBXU","BK4007","BK4585","IDNA","LU0208291251.USD","IE0002141913.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664887912","title":"FutureChem sets final issue price for paid-in capital increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2664887912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664887912?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:46","pubTimestamp":1788230764,"startTime":"0","endTime":"0","summary":"FutureChem Co., Ltd. ( ($KR:220100) ) has issued an announcement. FutureChem Co., Ltd., a KOSDAQ-listed radiopharmaceutical and biotech company, ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/futurechem-sets-final-issue-price-for-paid-in-capital-increase?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIB","XBIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881893","title":"Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881893","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664881893?lang=en_us&edition=fundamental","pubTime":"2026-09-01 07:30","pubTimestamp":1788219000,"startTime":"0","endTime":"0","summary":"An Important Step Forward for Access to LEQEMBI for Eligible Patients in CanadaTOKYO and CAMBRIDGE, Mass., Aug.  31, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353756/0/en/canada-s-drug-agency-issues-final-positive-recommendation-supporting-public-reimbursement-of-leqembi-lecanemab-for-early-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOCL","MCI","BMED","NVIB","MEDX","IDNA","GDOC","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883188","title":"NeuroThera Labs Advances Enrollment in Autism Drug Trial for SCI-210","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883188","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883188?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:37","pubTimestamp":1788208671,"startTime":"0","endTime":"0","summary":"NeuroThera Labs Inc. ( ($TSE:NTLX) ) has issued an update. NeuroThera Labs reported strong enrollment momentum in its SCI-210 clinical trial for ch...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/neurothera-labs-advances-enrollment-in-autism-drug-trial-for-sci-210?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX","HYLG","GDOC","IDNA","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883886","title":"Vogenx initiated with a Buy at Jones","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883886","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883886?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:15","pubTimestamp":1788207318,"startTime":"0","endTime":"0","summary":"Jones initiated coverage of Vogenx (VOGX) with a Buy rating and $55 price target Vogenx is a clinical-stage metabolic-focused biotech company, with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vogenx-initiated-with-a-buy-at-jones-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NVIB","XBIX","VOGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664883858","title":"SciSparc subsidiary provides update on SCI-210 trial enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2664883858","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664883858?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:10","pubTimestamp":1788207046,"startTime":"0","endTime":"0","summary":"SciSparc (SPRC)announced that NeuroThera Labs continued advancement in participant enrollment for the clinical trial assessing NeuroThera’s SCI-210...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scisparc-subsidiary-provides-update-on-sci-210-trial-enrollment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","HYLG","BK4139","IDNA","BK4007","MEDX","SPRC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664831883","title":"PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2664831883","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664831883?lang=en_us&edition=fundamental","pubTime":"2026-09-01 04:05","pubTimestamp":1788206710,"startTime":"0","endTime":"0","summary":"PMV Pharmaceuticals (PMVP) announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pmv-pharmaceuticals-announces-updated-ovarian-cancer-data-from-pynnacle-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","IDNA","PMVP","BK4139","MEDX","GDOC","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663588047","title":"Protagonist announces Takeda received U.S. FDA approval for MIMRYLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2663588047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663588047?lang=en_us&edition=fundamental","pubTime":"2026-08-31 04:35","pubTimestamp":1788122107,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-announces-takeda-received-u-s-fda-approval-for-mimrylo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","PSCH","TECB","IYH","RSPH","BMED","LABU","NVIB","SYNB","XLVX","GDOC","MRNX","TBXU","PINK","GNMX","LFSC","IEIH","MEDI","TAK","BBP","BK4585","FRTY","IBB","BK4139","IDNA","BK4007","MRNY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":170,"code":"91000000","status":"200"}]}}